The global Derma Fillers Market, valued at US$3.74 billion in 2024 stood at US$4.13 billion in 2025 and is projected to ...

Growth is driven by the increasing prevalence of neurological disorders like Alzheimer's, Parkinson's, and schizophrenia, ...

The company, which generated revenue of $2.83 billion in the last twelve months and maintains a market capitalization of $2.44 billion, has shown strong revenue growth of ~13% year-over-year. The ...

The company, which generated revenue of $2.83 billion in the last twelve months and maintains a market capitalization of $2.44 billion, has shown strong revenue growth of ~13% year-over-year.

The company, which generated revenue of $2.83 billion in the last twelve months and maintains a market capitalization of $2.44 billion, has shown strong revenue growth of ~13% year-over-year. The ...

BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of ...

REHOVOT, Israel, June 9, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its ...

In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.

REHOVOT, Israel, June 9, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its ...

REHOVOT, Israel, June 9, 2025 /PRNewswire/ — CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant ...

In addition, in a concurrent private placement, the Company will issue unregistered to purchase up to 1,200,002 of the Company's ordinary shares at an exercise price of $3.00 per share.